Exploring metabolic vulnerability and therapeutic potential in cancers with isocitrate dehydrogenase mutations
<p>Treatment of mutant isocitrate dehydrogenase 1 (IDH1) glioma remains challenging; targeted allosteric inhibitors currently provide limited clinical effect. Resistance to mutIDH1 inhibitors has also emerged in other cancers with mutant <em>IDH1</em>. IDH1 catalyses the decarboxyl...
| Prif Awdur: | |
|---|---|
| Awduron Eraill: | |
| Fformat: | Traethawd Ymchwil |
| Iaith: | Englihs |
| Cyhoeddwyd: |
2022
|
| Pynciau: |